All In Biotech

Drug Trial Radar · NCT02684006

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA(REGISTERED)) VERSUS SUNITINIB (SUTENT(REGISTERED)) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

Last checked: Nov 20, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 886 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

886

Actual

Start

Mar 23, 2016

Primary completion

Aug 31, 2023

Study completion Jun 26, 2024

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Feb 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma

Conditions

  • Renal Cell Cancer

Interventions

  • Avelumab (MSB0010718C)Drug

    IV treatment Avelumab administered at 10 mg/kg IV every two weeks

  • Axitinib (AG-013736)Drug

    Oral treatment Axitinib given 5 mg PO BID

  • SunitinibDrug

    Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive ParticipantsTime frame: From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)
  2. Overall Survival (OS) in PD-L1 Positive ParticipantsTime frame: From the date of randomization to the date of death due to any cause or censoring date, whichever occurred first (maximum up to approximately 89 months)

Locations

270 sites in 21 countries. Site status is shown where the registry gives one.

  • Southern Cancer Center

    Daphne, Alabama

  • Southern Cancer Center

    Mobile, Alabama

  • Southern Cancer Center

    Mobile, Alabama

  • Tower Hematology Oncology Medical Group

    Beverly Hills, California

  • City of Hope National Medical Center

    Duarte, California

  • City of Hope

    Duarte, California

  • Keck Hospital of USC

    Los Angeles, California

  • Los Angeles General Medical Center

    Los Angeles, California

  • USC IDS Pharmacy

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • Cedars-Sinai Advanced Health Sciences Pavilion

    Los Angeles, California

  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

    Los Angeles, California

  • Cedars-Sinai

    Los Angeles, California

  • Rocky Mountain Cancer Centers

    Aurora, Colorado

  • University of Colorado Cancer Center Anschutz Cancer Pavilion

    Aurora, Colorado

  • University of Colorado Hospital - Clinical Trials Office (CTO)

    Aurora, Colorado

  • University of Colorado Hospital

    Aurora, Colorado

  • Rocky Mountain Cancer Centers

    Colorado Springs, Colorado

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • Investigational Drug Service- Emory University

    Atlanta, Georgia

  • The Emory Clinic

    Atlanta, Georgia

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • East Jefferson General Hospital

    Metairie, Louisiana

  • East Jefferson Hematology-Oncology Metairie Physician Service Inc.

    Metairie, Louisiana

  • New England Cancer Specialists

    Kennebunk, Maine

  • New England Cancer Specialists

    Scarborough, Maine

  • New England Cancer Specialists

    Topsham, Maine

  • Oncology Investigational Drug Services- The Sidney Kimmel Cancer Center at Johns Hopkins Hospital

    Baltimore, Maryland

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • Massachusetts General Hospital (MGH)

    Boston, Massachusetts

  • Massachusetts General Hospital Clinical Trials Pharmacy

    Boston, Massachusetts

  • Brigham & Women's Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center (BIDMC)

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center Pharmacy - BIDMC

    Boston, Massachusetts

  • Dana - Farber Cancer Institute

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Baystate Franklin Medical Center

    Greenfield, Massachusetts

Showing 40 of 270 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.